Thursday, October 17, 2024 10:35:24 PM
The article tries to highlight the positive aspects of the news, however no mention of RMAT designation, and what that would mean to the timeline of approval.
The timeline outlined is a much longer duration for approval then the timeline generally speaking under RMAT designation. I could cite examples of 6-12 months for previous approvals under RMAT designation by other biotech companies.
Secondly, it's designated for patients that have no alternative, so imo, why should it not be fast tracked for approval if the safety and efficacy are there? Sometimes things don't make sense.
Don't mean to sound negative, however i was disappointed with this news.
The timeline outlined is a much longer duration for approval then the timeline generally speaking under RMAT designation. I could cite examples of 6-12 months for previous approvals under RMAT designation by other biotech companies.
Secondly, it's designated for patients that have no alternative, so imo, why should it not be fast tracked for approval if the safety and efficacy are there? Sometimes things don't make sense.
Don't mean to sound negative, however i was disappointed with this news.
Recent IMTX News
- Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 05/30/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 09:03:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 11:08:04 AM
- Immatics Announces First Quarter 2026 Financial Results and Business Update • GlobeNewswire Inc. • 05/12/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/21/2026 02:40:20 PM
- Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 02:25:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/17/2026 07:06:45 PM
- PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma • GlobeNewswire Inc. • 04/17/2026 07:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:41:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:39:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:39:40 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:36:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:31:07 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:27:51 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:26:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:15:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:08:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:07:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 10:49:10 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:01:29 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2026 12:12:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:00:37 PM
- Immatics Announces Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 03/05/2026 12:00:00 PM
